Mendelian randomization study reveals distinct effects of lipid-lowering drug targets on breast and endometrial cancer risk, highlighting specific oncologic safety profiles.
Our study demonstrated genetically that HMGCR inhibition, APOB inhibition, and NPC1L1 inhibition decrease the risk of breast cancer, LPL agonist increases the risk of endometrial cancer, and APOC3 inhibition decreases the risk of breast cancer and endometrial cancer, and these findings provide genetic insights into the potential risks of lipid-lowering drug therapy.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: